Frontier Clinical Research, LLC | Scottdale, PA

Research site

(Unclaimed)

Location

109 Crossroads Road Suite 301, Scottdale, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Relamorelin

Tenapanor

LY573144

Lasmiditan

Linaclotide

Tiotropium

Baloxavir Marboxil

Favipiravir

Norketotifen

Atogepant

Parent organization

This site is a part of Frontier Clinical Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 19 total trials

Locations recently updated

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling

Migraine

Drug: Lasmiditan

Locations recently updated

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling

Migraine

Drug: Placebo

Drug: Lasmiditan

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequ...

Active, not recruiting

Type 2 Diabetes

Drug: Orforglipron

Drug: Placebo

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (VALOR)

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North...

Active, not recruiting

Lyme Disease

Biological: VLA15

Other: Saline

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Invitation-only

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor 50 MG

Drug: Placebo